Security key
29337E102
Enliven Therapeutics, Inc. - COMMON STOCK (ELVN)
CUSIP: 29337E102
Q2 2023 13F Holders as of 30 Jun 2023
- Security type / class
- Equity / COMMON STOCK
- Total 13F shares
- 39,092,843
- Total 13F value
- $797,915,923
- Share change
- +5,535,094
- Put/Call ratio
- 0%
- SEC-reported price per share
- $20.41
- Number of holders
- 61
- Value change
- +$112,876,379
- Number of buys
- 43
- Number of sells
- 16
- Shares outstanding
- 71,310,600
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2023
Institutions
61
Top holders
10
ELVN full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2023
Previous quarter: Q1 2023
Enliven Therapeutics, Inc. SEC filings
Enliven Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 29337E102
Recent filing periods:
Ownership snapshot
Top reported holders of ELVN - Enliven Therapeutics, Inc. - COMMON STOCK (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ORBIMED ADVISORS LLC
Disclosed value leader
ORBIMED ADVISORS LLC
Comparable rows
15/15
Latest evidence
31 Mar 2023
13F
3/4/5
Lead comparable stake: 13%
Showing 1-6 of 15 holder rows.
Quick read
ORBIMED ADVISORS LLC leads the comparable SEC ownership view at 13%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ORBIMED ADVISORS LLC's linked filing trail.
Comparable ownership
Top 5
ORBIMED ADVISORS LLC
13%
5AM Venture Management, LLC
8.1%
FMR LLC
4.4%
CITADEL ADVISORS LLC
3.2%
Venrock Adviser, LLC
3.1%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC |
13F
Company
|
13%
|
$197,017,065
8,996,213 shares
|
— | 31 Mar 2023 |
| 5AM Venture Management, LLC |
13F
Company
|
8.1%
|
$126,986,603
5,798,475 shares
|
— | 31 Mar 2023 |
| FMR LLC |
13F
Company
|
4.4%
|
$69,280,255
3,163,482 shares
|
— | 31 Mar 2023 |
| CITADEL ADVISORS LLC |
13F
Company
|
3.2%
|
$50,286,999
2,296,210 shares
|
— | 31 Mar 2023 |
| Venrock Adviser, LLC |
13F
Company
|
3.1%
|
$48,489,710
2,214,142 shares
|
— | 31 Mar 2023 |
| RA CAPITAL MANAGEMENT, L.P. |
13F
3/4/5
Company · Former 10% owner
|
3%
|
$46,481,984
2,122,465 shares
|
— | 31 Mar 2023 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2023
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
61
Shares
39,092,843
Rows available
61
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2023 vs Q1 2023 Across Filers
Q1 2023 holders
44
Q2 2023 holders
61
Holder diff
17
| Investor | Q1 2023 Shares | Q2 2023 Shares | Share Diff | Share Chg % | Q1 2023 value | Q2 2023 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend